Prospective Observational Clinical Follow-up of Euromi Biosciences Pre-filled Silicone Gel Breast Implants

Last updated: November 28, 2023
Sponsor: Euromi Biosciences
Overall Status: Active - Recruiting

Phase

N/A

Condition

N/A

Treatment

Breast reconstruction

Clinical Study ID

NCT05987475
ID RCB: 2023-A00101-44
  • Ages 18-60
  • Female
  • Accepts Healthy Volunteers

Study Summary

Prospective observational clinical follow-up of Euromi Biosciences silicone gel-filled breast implants - Post-market clinical investigation - ELEGANT

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Female;
  • 18 years old and above, and under 60 years old;
  • has approved and signed the informed consent form;
  • eligible to receive at least one EUROMI Biosciences implant during breastreconstruction following a mastectomy or during aesthetic breast surgery;
  • Willing to be followed up for a period of 10 years.

Exclusion

Exclusion Criteria:

  • Informed pregnancy or breastfeeding at the time of inclusion
  • Known hypersensitivity and / or allergy to silicone;
  • Not understanding or not accepting the risks of further surgeries during follow-up;
  • Body mass index > 40 kg/m²;
  • Diabetes
  • HbA1c levels > 7,5%;
  • History of repeated failure with the implantation of similar implants;
  • Tissue or fat insufficiency;
  • Progressive breast cancer large tumours (>5 cm), late cancer stage and deep tumours;
  • Grossly positive axillary involvement / or chest wall involvement;
  • High risk of cancer recurrence;
  • Tissue damage in the implant area due to irradiation of the thoracic wall;
  • Pre-existing pathology in the implant area;
  • General infection or infection in the implant area;
  • Medical condition (poor physiological condition, psychological instability, severesmoking, obesity, coagulopathy, diabetes, severe cardiovascular or pulmonary disease,etc.) Which may, according to the judgement of the surgeon, entail excessive riskand/or post-surgical complications;
  • History or presence of an autoimmune disease;
  • Immunocompromised;
  • History or current treatment using radiation with lower-pole scarring and thin, poorlyvascularized skin/tissue / microwave diathermy / or steroids;
  • Medical condition likely to interfere with her capacity to understand the follow-uprequirements, to participate in the follow-up or to give her informed consent;
  • Concomitantly part of another interventional clinical trial.
  • Under supervision or legal guardianship
  • Deprived of liberty by a judicial or administrative decision
  • Not affiliated to health insurance system or is a beneficiary of such coverage

Study Design

Total Participants: 177
Treatment Group(s): 1
Primary Treatment: Breast reconstruction
Phase:
Study Start date:
October 18, 2023
Estimated Completion Date:
September 30, 2034

Connect with a study center

  • CHRU Nancy

    Nancy,
    France

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.